JACOBIO PHARMACEUTICALS GROUP CO., LTD. Jacobio Pharmaceuticals Group Co., Ltd. Stock
Equities
1167
KYG4987A1094
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.69 HKD | -2.31% |
|
+15.75% | -53.31% |
| 04-25 | Jacobio Pharmaceuticals Plans Auditor Change | MT |
| 04-09 | Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention | MT |
| Sales 2023 | 63.52M 8.77M 68.64M 12.07M | Sales 2024 * | - | Capitalization | 1.24B 171M 1.34B 235M |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 | 25.1 x |
| Net cash position 2023 | 1.01B 140M 1.09B 192M | Net cash position 2024 * | 462M 63.88M 500M 87.86M | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 301 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 55.92% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.31% | ||
| 1 week | +15.75% | ||
| Current month | +4.32% | ||
| 1 month | +4.32% | ||
| 3 months | -35.98% | ||
| 6 months | -56.56% | ||
| Current year | -53.31% |
1 week
1.42
1.84
1 month
1.381.84
Current year
1.383.71
1 year
1.387.77
3 years
1.3824.60
5 years
1.3825.35
10 years
1.3825.35
| Managers | Title | Age | Since |
|---|---|---|---|
Yin Xin Wang
CEO | Chief Executive Officer | 59 | 18-05-31 |
Hai Jun Wang
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Tech/Sci/R&D Officer | 54 | 20-07-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rui Lin Song
BRD | Director/Board Member | 61 | 20-08-19 |
Xiaojie Wang
ADM | Chief Administrative Officer | 60 | 18-07-30 |
Yun Yan Hu
BRD | Director/Board Member | 61 | 18-07-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.85% | 4 M€ | -27.92% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 1.69 | -2.31% | 751,800 |
| 24-04-29 | 1.73 | +2.37% | 1,256,400 |
| 24-04-26 | 1.69 | +5.62% | 818,400 |
| 24-04-25 | 1.6 | +5.26% | 413,400 |
| 24-04-24 | 1.52 | +4.11% | 568,200 |
Delayed Quote Hong Kong S.E., April 30, 2024 at 04:08 am
More quotes
Jacobio Pharmaceuticals Group Co Ltd is a China-based investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly conducts business within the domestic market.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.564
CNY
Average target price
3.954
CNY
Spread / Average Target
+152.81%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -53.31% | 175M | |
| -3.46% | 102B | |
| +1.41% | 96.29B | |
| +2.13% | 22.18B | |
| -15.84% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -14.65% | 16.36B | |
| +4.39% | 13.97B | |
| +31.35% | 12.17B |
- Stock Market
- Equities
- 1167 Stock
